REV-ERB agonism improves liver pathology in a mouse model of NASH

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis

(2020) Stergios A. Polyzos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

(2020) Gong Feng et al.   GENE

Nuclear Receptor Subfamily 1 Group D Member 1 Regulates Circadian Activity of NLRP3 Inflammasome to Reduce the Severity of Fulminant Hepatitis in Mice

(2018) Benoit Pourcet et al.   GASTROENTEROLOGY

Circadian clock component REV-ERBα controls homeostatic regulation of pulmonary inflammation

(2018) Marie Pariollaud et al.   JOURNAL OF CLINICAL INVESTIGATION

Pharmacotherapy for NASH: Current and emerging

(2018) Monica A. Konerman et al.   JOURNAL OF HEPATOLOGY

Targeting nuclear receptors for the treatment of fatty liver disease

(2017) Naoki Tanaka et al.   PHARMACOLOGY & THERAPEUTICS

Rev-erb agonist improves adverse cardiac remodeling and survival in myocardial infarction through an anti-inflammatory mechanism

(2017) Endin Nokik Stujanna et al.   PLoS One

Promiscuous activity of the LXR antagonist GSK2033 in a mouse model of fatty liver disease

(2016) Kristine Griffett et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis

(2016) Eleonora Scorletti et al.   DIGESTIVE DISEASES

Epidemiology and natural history of non-alcoholic fatty liver disease

(2016) Yousef Fazel et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Suppression of atherosclerosis by synthetic REV-ERB agonist

(2015) Sadichha Sitaula et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis

(2015) Kristine Griffett et al.   Molecular Metabolism

Obesity, Type 2 diabetes and NAFLD

(2014)   DIABETIC MEDICINE

Novel role of nuclear receptor rev-erbα in hepatic stellate cell activation: Potential therapeutic target for liver injury

(2014) Ting Li et al.   HEPATOLOGY

A Liver-Selective LXR Inverse Agonist That Suppresses Hepatic Steatosis

(2012) Kristine Griffett et al.   ACS Chemical Biology

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

(2012) James L. Trevaskis et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists

(2012) Laura A. Solt et al.   NATURE

A Role for Rev-erbα Ligands in the Regulation of Adipogenesis

(2011) Douglas J. Kojetin et al.   CURRENT PHARMACEUTICAL DESIGN